Celestica's Next Leg Higher

Celestica reported Q4 revenue of $3.65B, up 44% YoY, and Q4 EPS of $1.89, up 70% (FY EPS +98%), driven by 800G networking and AI compute deployments and strong operating leverage. Management's 2026 outlook implies ~$17B in revenue (+37%) and ~$8.75 EPS (~45% growth), with CCS cited as the primary driver and hyperscaler demand cycles underpinning growth.

Analysis

Scale winners are being re-priced: a handful of EMS players with deep hyperscaler relationships, control of optical/substrate sourcing and in-house thermal/assembly capabilities will disproportionately capture next-wave 800G/AI compute spend while smaller EMS peers face margin pressure and customer defection. Downstream component vendors (high-speed optics, advanced PCBs, silicon photonics partners) should see order concentration that improves lead times for preferred suppliers and compresses availability for the long tail, creating a two-tier supply chain within 6–12 months.

Key catalysts and reversals are concentrated and time-sensitive. Near-term (days–weeks) direction will be driven by positioning and options gamma around the print and any incremental color on customer cadence; medium term (3–12 months) the critical tests are order durability from the top 3 hyperscalers and whether CCS adoption is expanding stickily rather than a one-off absorption event. Tail risks include rapid hyperscaler inventory digestion, a softening in non-AI enterprise networking demand, or a component oversupply that erodes pricing power—any of which can flip margins in a single quarter.

Trade implementation should favor asymmetric, capped-loss structures and relative-value exposure to isolate scale/AI compute optionality while hedging cyclicality. Use 6–12 month expiries to capture continued customer deployments but keep exposure size-conscious: this cycle is high conviction on structural share gains but binary on cadence. Monitor accounts payables, backlog cadence and customer-level revenue disclosures as daily/weekly signals.

Contrarian angle: the market may be under-discounting customer concentration and front-loaded order timing—guidance volatility is likely even if long-run secular demand holds. Conversely, if supply tightness persists, preferred suppliers could sustain outsized margins for multiple years; trade selection should therefore separate scale/execution winners from volume-sensitive peers within the next 12–24 months.

Key Decisions for Investors

• Buy CLS (CLS) equity, 12-month horizon: allocate 2–4% portfolio, target ~+40% upside vs ~-18% stop-loss. Rationale: capture scale premium while maintaining a tight downside cut if cadence softens.
• Pair trade — Long CLS / Short FLEX (FLEX) equal notional, 6–12 months: objective +25–35% relative return if scale-driven margin divergence continues; stop-loss if spread moves against by 15%. This isolates AI/hyperscaler exposure versus consumer/low-margin EMS cyclical risk.
• Options asymmetric — Buy 9-month CLS call spread (buy ATM call, sell 30% OTM call): defined max loss = premium, target 2.0–3.0x payoff if stock > +25–30% in 9 months. Use instead of naked longs to limit capital at risk to inventory/cadence shocks.
• Event hedge — Buy 3–6 month puts on CLS sized to cover 25–30% of long exposure if you hold equity into next results: cost is insurance against a sudden pull-in/pullback from hyperscalers that would materially compress near-term backlog visibility.